Business Wire

Verimatrix and TELUS Team Up to Showcase First-of-Its Kind Piracy Protections for New Optik TV at IBC 2023

Share

Regulatory News:

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, will showcase how Verimatrix Streamkeeper was integrated with the next generation of TELUS’ Optik TV platform to create an advanced, industrial-scale video content delivery platform that uniquely prevents video piracy and keeps valuable entertainment secure at IBC 2023.

TELUS, a world-leading communications technology company, needed to securely deliver premium video content across platforms to millions of Canadian customers. They deployed the Verimatrix Streamkeeper platform, which combines Multi-DRM, advanced anti-piracy protections and analytics in a single scalable solution. This enabled robust security for video on demand (VOD) and live content while optimizing operations. Verimatrix Streamkeeper supports a range of Digital Rights Management (DRMs) and integrations to work across TELUS's delivery network, including set-top boxes, mobile apps, and web streaming. The cloud-based architecture brings efficiency, flexibility, and failover capabilities. Together, Verimatrix and TELUS created an innovative solution with a usage-based model to enable TELUS to confidently distribute premium video experiences today and in the future across its hybrid cloud and on-premises infrastructure.

Geartech Technologies also served as an invaluable partner in the anti-piracy and content protection solution for TELUS. As a distributor and supplier of innovative broadcast solutions, Geartech leveraged their expertise to recommend Verimatrix as the ideal provider to help TELUS ensure protection of their digital assets.

Streamlined integration and a smooth migration path were unwavering requirements for Tom Linder, Director of Content & Consumer DevOps at TELUS:

"We couldn't be more excited to bring our new content delivery solution to market. The team has worked tirelessly to create a truly next-gen content and digital life platform, and we needed a partner who not only shared our vision, but who could listen, adapt, customize and suggest the best path forward. By integrating Verimatrix Streamkeeper's layered approach to security, we have an incredibly powerful and future-proof system that will serve our customers well for years to come."

"It has been exciting to work with TELUS to deploy their next-generation TV and over the top streaming platform,” said Sofia Regojo, Chief Revenue Officer at Verimatrix. “Partnering with fellow innovators such as TELUS means leveraging each other's expertise to push boundaries and achieve more together. It means having open conversations to inspire new ideas and constructively challenging each other to find the best path forward. Most importantly, it means maintaining a shared vision to create solutions that truly make a difference.”

"Piracy continues evolving in smart, unpredictable ways," said Maria Malinkowitsch, Senior Product Manager for Streamkeeper at Verimatrix. "Safeguarding content is no longer enough. Today’s modern solutions must also secure vulnerable edges, at scale, and include real-time cybersecurity countermeasures that won't affect the viewer experience."

The two companies will appear on a panel discussion together at IBC 2023 taking place September 17 in Amsterdam and moderated by Andy Waltenspiel, a broadcast industry veteran. Additionally, an innovation story video will be featured at the Verimatrix IBC booth #1.D81.

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com

Verimatrix Media Contacts:
USA
Matthew Zintel, Zintel Public Relations
matthew.zintel@zintelpr.com

Europe
Lara Joseph, Eskenzi PR
lara@eskenzipr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye